Scholarlink

<p>Polycystic ovary syndrome (PCOS) is a complex endocrine disorder characterized by heterogeneous symptoms and is commonly managed with conventional medications that often exhibit variable efficacy and undesirable side effects. Given these limitations, nanotechnology, particularly plant-derived metallic nanoparticles, offers novel strategies to enhance phytochemical delivery, stability, and bioavailability. Accordingly, this scoping review synthesizes preclinical evidence (2015–2025) on plant-derived metallic nanoparticles for PCOS, evaluating therapeutic outcomes, safety, and mechanisms. In line with PRISMA-ScR guidance, records were identified from PubMed, Scopus, and ScienceDirect (<i>n</i> = 375), duplicates were removed (<i>n</i> = 51), and 324 records underwent screening. Three hundred twenty records were excluded based on title/abstract screening, and 4 reports were retrieved from databases for eligibility assessment. Together with 1 additional study from Google Scholar, 5 rodent studies were included. Reporting quality and risk of bias were assessed descriptively using selected ARRIVE- and SYRCLE-based domains. Overall, the included studies evaluated <i>cinnamon</i>-derived silver nanoparticles, selenium nanoparticles synthesized using <i>Corchorus olitorius</i>, silver nanoparticles synthesized from aqueous extract of fresh <i>asparagus</i> stems, and silver nanoparticles prepared using <i>fenugreek</i> aqueous extract. Across the included studies, these interventions normalized reproductive hormones, restored estrous cyclicity and fertility, reduced ovarian cystic changes, and lowered inflammatory markers (TNF-α, IL-6, IL-10, IL-17, IL-18) without observable toxicity. Nevertheless, clinical translation remains pending due to the absence of long-term safety data and well-structured human clinical trials. Future research should prioritize mechanistic validation, long-term toxicological assessment, formulation standardization, and rigorously designed clinical trials.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Exploring the role of medicinal plants and nanotechnology in the management of polycystic ovarian syndrome (PCOS): a scoping review

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月14日

查看全文
  • Obukowho Benson Ichipi,
  • Samuel Oluwaseun Olojede,
  • Sodiq Kolawole Lawal,
  • Onyemaechi Okpara Azu,
  • Edwin Coleridge Naidu

摘要

Polycystic ovary syndrome (PCOS) is a complex endocrine disorder characterized by heterogeneous symptoms and is commonly managed with conventional medications that often exhibit variable efficacy and undesirable side effects. Given these limitations, nanotechnology, particularly plant-derived metallic nanoparticles, offers novel strategies to enhance phytochemical delivery, stability, and bioavailability. Accordingly, this scoping review synthesizes preclinical evidence (2015–2025) on plant-derived metallic nanoparticles for PCOS, evaluating therapeutic outcomes, safety, and mechanisms. In line with PRISMA-ScR guidance, records were identified from PubMed, Scopus, and ScienceDirect (n = 375), duplicates were removed (n = 51), and 324 records underwent screening. Three hundred twenty records were excluded based on title/abstract screening, and 4 reports were retrieved from databases for eligibility assessment. Together with 1 additional study from Google Scholar, 5 rodent studies were included. Reporting quality and risk of bias were assessed descriptively using selected ARRIVE- and SYRCLE-based domains. Overall, the included studies evaluated cinnamon-derived silver nanoparticles, selenium nanoparticles synthesized using Corchorus olitorius, silver nanoparticles synthesized from aqueous extract of fresh asparagus stems, and silver nanoparticles prepared using fenugreek aqueous extract. Across the included studies, these interventions normalized reproductive hormones, restored estrous cyclicity and fertility, reduced ovarian cystic changes, and lowered inflammatory markers (TNF-α, IL-6, IL-10, IL-17, IL-18) without observable toxicity. Nevertheless, clinical translation remains pending due to the absence of long-term safety data and well-structured human clinical trials. Future research should prioritize mechanistic validation, long-term toxicological assessment, formulation standardization, and rigorously designed clinical trials.